Devonian's Thykamine Shows Dose-Dependent Anti-Fibrotic Effects in Human Liver-on-a-Chip Study
Event summary
- Devonian's Thykamine™ demonstrated dose-dependent anti-fibrotic and anti-inflammatory effects in a human liver-on-a-chip model, reducing fibrosis biomarkers and collagen deposition.
- The study, conducted by CN Bio Innovations, used the PhysioMimix® Liver-on-a-Chip platform to evaluate Thykamine™ at four concentrations over a 14-day period.
- Thykamine™ showed stronger collagen reduction than Elafibranor, a clinically advanced compound, under identical experimental conditions.
- Devonian plans to advance additional preclinical studies to further characterize Thykamine™'s disease-modifying potential in MASH and other fibrotic diseases.
The big picture
Devonian's positive preclinical data for Thykamine™ in a human liver-on-a-chip model strengthens its translational rationale as a potential disease-modifying therapeutic candidate for MASH. The global MASH treatment market is projected to grow at a 17.7% CAGR from 2025 to 2033, driven by rising rates of obesity, type 2 diabetes, and metabolic syndrome. This study represents a critical step in bridging in vivo and human organ-on-a-chip models, supporting Thykamine™'s differentiated profile among emerging MASH therapeutics.
What we're watching
- Clinical Translation
- Whether Thykamine™'s efficacy in human liver-on-a-chip models will translate to clinical success in MASH patients.
- Competitive Positioning
- How Devonian's differentiated profile among emerging MASH therapeutics will impact its market positioning against established competitors like Elafibranor.
- Preclinical Development
- The pace at which Devonian advances additional preclinical studies to further characterize Thykamine™'s disease-modifying potential.
Related topics